Ivermectin Glenmark

Ivermectin, the active ingredient in Ivermectin Glenmark, is an anthelmintic presented as an oral tablet for oral use. It treats a range of parasitic infections in both adults and children, including river blindness, strongyloidiasis, filariasis, scabies, lice and other related conditions worldwide.

GNH USA supplies Ivermectin Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures consistent quality and regulatory compliance across all shipments, and our distribution network reaches key markets in Europe, Asia, Africa and the Americas, facilitating reliable access for healthcare providers.

Ivermectin is an antiparasitic drug that targets a variety of helminth and ectoparasite infections.

Onchocerciasis: reduces microfilarial load and prevents disease progression. Strongyloidiasis: eliminates intestinal larvae and prevents dissemination. Lymphatic filariasis: decreases adult worm burden and reduces transmission. Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions. Pediculosis: kills head lice and nits, controlling infestation. Intestinal helminth infections: clears common roundworm and hookworm infections, improving gastrointestinal health.

Ivermectin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Dizziness - Headache - Pruritus

Serious or Rare Side Effects: - Stevens‑Johnson syndrome - Encephalopathy - Severe skin reactions - Hepatic injury - Visual disturbances - Anaphylaxis

When prescribing ivermectin, several safety considerations should be observed.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Breastfeeding: unknown; consider potential exposure to infant. Liver disease: use with caution; monitor hepatic function. Concomitant CNS depressants: may increase neurotoxicity risk. Drug interactions: review all concomitant medications. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ivermectin can interact with other medicines, affecting its concentration or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase ivermectin plasma levels. - Warfarin: potential enhancement of anticoagulant effect. - P‑glycoprotein inhibitors: increase systemic exposure. - Other antiparasitics: risk of additive toxicity. - Neuroactive GABAergic agents: heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce efficacy. - Antacids: may affect absorption. - Macrolide antibiotics: potential pharmacokinetic interaction. - Statins: monitor for muscle toxicity. - Antifungals (e.g., ketoconazole): may alter ivermectin levels.